Search results for "CD33"

showing 7 items of 7 documents

Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade

2019

Abstract Purpose: Hyperprogression (HP), a paradoxical boost in tumor growth, was described in a subset of patients treated with immune checkpoint inhibitors (ICI). Neither clinicopathologic features nor biological mechanisms associated with HP have been identified. Experimental Design: Among 187 patients with non–small cell lung cancer (NSCLC) treated with ICI at our institute, cases with HP were identified according to clinical and radiologic criteria. Baseline histologic samples from patients treated with ICI were evaluated by IHC for myeloid and lymphoid markers. T-cell–deficient mice, injected with human lung cancer cells and patient-derived xenografts (PDX) belonging to specific mutat…

0301 basic medicineMaleCancer ResearchMyeloidLung NeoplasmsCD33Programmed Cell Death 1 ReceptorFc receptorMice NudeMice SCIDReceptors Fcnon-small cell lung cancer Hyperprogression immune checkpoint inhibitors.B7-H1 AntigenArticle03 medical and health sciences0302 clinical medicineImmunophenotypingAntineoplastic Agents ImmunologicalPD-L1Carcinoma Non-Small-Cell LungCell Line TumormedicineAnimalsHumansLung cancerAntibodies Blockingbiologybusiness.industryMacrophagesmedicine.diseaseXenograft Model Antitumor Assays3. Good healthImmunoglobulin Fc FragmentsTumor Burden030104 developmental biologymedicine.anatomical_structureNivolumabOncology030220 oncology & carcinogenesisbiology.proteinCancer researchImmunohistochemistryFemaleAntibodybusinessClinical Cancer Research
researchProduct

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

2005

BACKGROUND In this study, the authors analyzed the efficacy and safety of gemtuzumab ozogamicin (GO) (Mylotarg®), an antibody-targeted chemotherapy for CD33-positive acute myeloid leukemia (AML). METHODS Patients with CD33-positive AML in first recurrence were entered in 3 open-label, single-arm, Phase II studies. Patients received monotherapy with GO 9 mg/m2 as a 2-hour intravenous infusion in 2 doses separated by 2 weeks. Patients were evaluated for remission, survival, and treatment-emergent adverse events. RESULTS Two hundred seventy-seven patients (median age, 61 yrs) were treated with GO, and 71 patients (26%) achieved remission, which was defined as ≤ 5% blasts in the bone marrow wit…

AdultMaleCancer Researchmedicine.medical_specialtyMyeloidMaximum Tolerated DoseGemtuzumab ozogamicinmedicine.medical_treatmentCD33Sialic Acid Binding Ig-like Lectin 3Antigens Differentiation MyelomonocyticHematopoietic stem cell transplantationNeutropeniaAntibodies Monoclonal HumanizedGastroenterologyRisk AssessmentSeverity of Illness IndexDrug Administration ScheduleClinical Trials Phase II as TopicAntigens CDRecurrenceInternal medicinemedicineHumansSingle-Blind MethodSurvival rateAgedAged 80 and overChemotherapyDose-Response Relationship Drugbusiness.industryAntibodies MonoclonalMiddle Agedmedicine.diseaseGemtuzumabSurgerySurvival RateLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureAminoglycosidesTreatment OutcomeOncologyEvaluation Studies as TopicFemalebusinessmedicine.drugFollow-Up StudiesCancer
researchProduct

Myeloid-Derived Suppressor Cells in Multiple Myeloma: Pre-Clinical Research and Translational Opportunities

2014

Immunosuppressive cells have been reported to play an important role in tumor-progression mainly because of their capability to promote immune-escape, angiogenesis, and metastasis. Among them, myeloid-derived suppressor cells (MDSCs) have been recently identified as immature myeloid cells, induced by tumor-associated inflammation, able to impair both innate and adaptive immunity. While murine MDSCs are usually identified by the expression of CD11b and Gr1, human MDSCs represent a more heterogeneous population characterized by the expression of CD33 and CD11b, low or no HLA-DR, and variable CD14 and CD15. In particular, the last two may alternatively identify monocyte-like or granulocyte-lik…

Cancer ResearchAngiogenesisCD33MDSCInflammationReview Articlelcsh:RC254-282Immune systemImmunesuppressionmedicinecancerimmunosuppressionbusiness.industryAcquired immune systemlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenspreclinical modelsmedicine.anatomical_structuremyelomaOncologyTumor progressionImmunologyMyeloid-derived Suppressor CellBone marrowmedicine.symptombusinesspre-clinical modelsFrontiers in Oncology
researchProduct

Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

2020

Granulocytic myeloid-derived suppressor cells (G-MDSCs) promote tumor growth and immunosuppression in multiple myeloma (MM). However, their phenotype is not well established for accurate monitoring or clinical translation. We aimed to provide the phenotypic profile of G-MDSCs based on their prognostic significance in MM, immunosuppressive potential, and molecular program. The preestablished phenotype of G-MDSCs was evaluated in bone marrow samples from controls and MM patients using multidimensional flow cytometry; surprisingly, we found that CD11b+CD14−CD15+CD33+HLADR− cells overlapped with common eosinophils and neutrophils, which were not expanded in MM patients. Therefore, we relied on …

MaleTranscription GeneticNeutrophilsT-LymphocytesImmunologyCD33BiologyCD16BiochemistryFollow-Up StudieFlow cytometryAntigens CDmedicineHumansCytotoxic T cellLymphocyte CountTumor microenvironmentmedicine.diagnostic_testMyeloid-Derived Suppressor CellsCell BiologyHematologyMiddle AgedCell sortingNeoplasm Proteinsmedicine.anatomical_structureT-LymphocyteCancer researchMyeloid-derived Suppressor CellFemaleBone marrowMultiple MyelomaHumanFollow-Up StudiesBlood
researchProduct

Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms

2021

High-grade Gastroenteropancreatic Neuroendocrine neoplasms (H-NENs) comprehend well-differentiated tumors (NET G3) and poorly differentiated carcinomas (NEC) with proliferative activity indexes as mitotic count (MC) &gt

Oncologymedicine.medical_specialtyMyeloidmyeloid markersT cellCD3gastroenteropancreatic neuroendocrine neoplasms; myeloid markers; tumor microenvironmentCD33PopulationHuman leukocyte antigenSettore MED/08 - Anatomia PatologicaArticleSurgical pathology03 medical and health sciences0302 clinical medicineInternal medicinemedicinetumor microenvironmenteducation030304 developmental biologymyeloid marker0303 health sciencesTumor microenvironmenteducation.field_of_studybiologybusiness.industryRGeneral Medicinegastroenteropancreatic neuroendocrine neoplasms myeloid markers tumor microenvironmentgastroenteropancreatic neuroendocrine neoplasmsstomatognathic diseasesmedicine.anatomical_structure030220 oncology & carcinogenesisgastroenteropancreatic neuroendocrine neoplasmbiology.proteinMedicinebusiness
researchProduct

Immunohistochemical Characterization of Human Synovial Bursa Cells by Light and Transmission Electron Microscopy: Where do These Cells Come From?

2007

En el presente estudio se examinaron bolsas sinoviales humanas a traves de microscopia de luz y electronica de transmision. Para la microscopia de luz, el tejido de las bolsas se tino con Azan, H-E y anticuerpos monoclonales (CD14, CD33, CD36, CD68, laminina). Para la microscopia electronica las bolsas fueron fijadas con solucion de Karnovsky y tetroxido de osmio al 1,5% (Os04) en agua destilada y contrastada con acetato de uranilo al 5% y embebido en Epon®. En primera instada, el fenotipo antigenico fue caracterizado, concluyendose acerca del origen de las celulas que componen la bolsa sinovial. Histologicamente la bolsa fue dividida en dos capas distintas - la intima - la cual es formada …

PhysicsBasal laminaendocrine systemanimal structuresSynovial bursaCD33 antigenAnatomyCD14 antigenCD68 antigenMolecular biology
researchProduct

Increased frequencies of CD11b+CD33+CD14+HLA-DRlowmyeloid-derived suppressor cells are an early event in melanoma patients

2014

Myeloid-derived suppressor cells (MDSC) are a heterogeneous cell population characterized by immunosuppressive activity. Elevated levels of MDSC in peripheral blood are found in inflammatory diseases as well as in malignant tumors where they are supposed to be major contributors to mechanisms of tumor-associated tolerance. We investigated the frequency and function of MDSC in peripheral blood of melanoma patients and observed an accumulation of CD11b(+) CD33(+) CD14(+) HLA-DR(low) MDSC in all stages of disease (I-IV), including early stage I patients. Disease progression and enhanced tumor burden did not result in a further increase in frequencies or change in phenotype of MDSC. By investig…

Skin Neoplasmsmedicine.medical_treatmentCD14Sialic Acid Binding Ig-like Lectin 3CD33PopulationLipopolysaccharide ReceptorsReceptors Antigen T-CellDermatologyBiologyLymphocyte ActivationT-Lymphocytes RegulatoryBiochemistryImmune toleranceTetanus ToxoidHLA-DRmedicineHumansMyeloid CellsLymphocyte CounteducationMelanomaMolecular BiologyCells CulturedCell ProliferationNeoplasm Stagingeducation.field_of_studyCD11b AntigenMelanomaInterleukin-8HLA-DR AntigensImmunotherapymedicine.diseaseCoculture TechniquesTumor BurdenCase-Control StudiesImmunologyDisease ProgressionLeukocytes MononuclearMyeloid-derived Suppressor CellTumor EscapeExperimental Dermatology
researchProduct